Prospective monitoring of prostate specific membrane antigen (PSMA) –positive recurrent prostate cancer: Preliminary data from 6 months PSMA follow-up.
Ravi A. Madan(National Cancer Institute), Peter L. Choyke(National Cancer Institute), Edwin M. Posadas(Cedars-Sinai Medical Center), Jeanny B. Aragon‐Ching(Inova Fairfax Hospital), Amy Hankin(National Institutes of Health), Laura A. Sena(Johns Hopkins University), Marijo Bilušić(National Institutes of Health), Fatima Karzai(National Institutes of Health), Esther Mena(National Institutes of Health), Philip M. Arlen(Dana-Farber Cancer Institute), Megan Hausler(National Institutes of Health), William D. Figg(National Cancer Institute), Liza Lindenberg(National Cancer Institute), Gregory T. Chesnut(Uniformed Services University of the Health Sciences), Russell K. Pachynski, Monique Williams(National Institutes of Health), Helen Moon(National Cancer Institute), Krishnan R. Patel(National Institutes of Health), Deborah Jolissaint(Walter Reed National Military Medical Center), Melissa L. Abel(National Institutes of Health)
Cited by 0
Related Papers
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817